UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 1, 2020

Arrowhead Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware 001-38042 46-0408024
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (626) 304-3400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

<table>
<thead>
<tr>
<th>Title of each class</th>
<th>Trading Symbol(s)</th>
<th>Name of each exchange on which register</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock, Par Value $0.001 per share</td>
<td>ARWR</td>
<td>The Nasdaq Global Select Market</td>
</tr>
</tbody>
</table>
Election of Oye Olukotun, M.D., MPH as a Director

At the recommendation of the Nomination Committee, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) elected Oye Olukotun, M.D., MPH, as an independent director of the Company with a term beginning effective September 1, 2020. On September 1, 2020, Mr. Olukotun accepted an appointment to the Board of Directors of Arrowhead Pharmaceuticals, Inc.

Mr. Olukotun’s compensation for the remainder of calendar 2020 will consist of cash compensation of $23,333 and a grant of 5,000 restricted stock units that will vest on the one-year anniversary of the grant date.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: September 8, 2020

ARROWHEAD PHARMACEUTICALS, INC.

By: /s/ Kenneth Myszkowski
   Kenneth Myszkowski
   Chief Financial Officer